Last updated: April 25, 2026
Who Supplies Melphalan Hydrochloride for Pharmaceutical Manufacturing?
What is Melphalan Hydrochloride and why supplier sourcing matters?
Melphalan hydrochloride is a cytotoxic chemotherapy active pharmaceutical ingredient (API) used in oncology regimens, most notably multiple myeloma and related plasma cell disorders. Supplier qualification affects:
- Regulatory compliance (DMF/CEP status, GMP track record)
- CMC stability (specs, impurity profiles, particle/appearance controls)
- Supply continuity (manufacturing location, batch size, lead times)
Who are the typical API supplier categories?
For melphalan hydrochloride, commercial supply typically comes from three categories:
- API manufacturers selling directly under GMP supply arrangements
- API distributors/brokers consolidating from API plants
- Company-owned CMO/contract API partners supplying branded or licensed products
Which suppliers are known to supply Melphalan Hydrochloride (API)?
The following suppliers are identified in public pharmaceutical procurement and regulatory ecosystems as melphalan hydrochloride API or melphalan hydrochloride raw-material supply sources (direct or through distribution).
| Supplier / Supplier group |
Supply role in market |
Evidence type (public ecosystem) |
| Aspen Global Inc. / Aspen Pharmaceuticals (Aspen) |
Market supplier/distributor footprint |
Listed product/packaging and supply ecosystem visibility |
| Viatris Inc. |
Market supplier/distributor footprint |
Listed product/packaging and supply ecosystem visibility |
| Teva Group |
Market supplier/distributor footprint |
Listed product/packaging and supply ecosystem visibility |
| Accord Healthcare |
Market supplier/distributor footprint |
Listed product/packaging and supply ecosystem visibility |
| Pfizer (legacy/market footprint depending on jurisdiction) |
Market supplier/distributor footprint |
Listed product/packaging visibility in some regions |
| Hospira / Pfizer legacy distribution |
Market supplier footprint |
Listed product/packaging visibility in some regions |
Important sourcing constraint: In many jurisdictions, official documentation (labels, SmPC, and manufacturing sites) ties to the finished-dose product rather than the melphalan hydrochloride API directly. Supplier names can therefore reflect the marketing authorization holder, MAH, or finished product manufacturer, not always the API plant.
How to pinpoint the actual API manufacturing site
Use a two-step mapping approach based on dossiers that are routinely available in regulatory and tender documentation:
- Start from the finished product (melphalan hydrochloride injection or tablet form where applicable)
- Extract the manufacturing/packaging/labeling sites from the Summary of Product Characteristics (SmPC) or regulator product listing
- Cross-check API manufacturing via DMF/CEP references (where explicitly stated in regulatory filings)
This mapping is necessary because supplier names on commercial listings often represent the MAH or finished-dose manufacturer rather than the API site.
What do buyers need to verify for qualified procurement?
How do CMC specs vary by supplier?
Even with the same API, supplier-to-supplier variation shows up in:
- Impurity spectrum (process-related impurities)
- Assay method and acceptance limits
- Particle attributes (for solid forms)
- Residual solvents and elemental impurities aligned with ICH Q3/Q4 frameworks
What documentation procurement typically requires
For melphalan hydrochloride API, buyers usually require:
- GMP certificate for the API manufacturing site (and any intermediates)
- Certificate of Analysis (CoA) for each lot
- Specification sheet (assay, impurities, water/LOI if applicable)
- Stability summary and re-test period rationale
- Regulatory status: DMF/CEP reference if the supplier participates
What supply risk flags matter
Common risk indicators when comparing suppliers:
- Single-site dependency (no secondary manufacturing)
- Low batch frequency (reduced ability to meet surge demand)
- High change control activity (API process adjustments)
- Regulatory findings at API plants (if disclosed in public enforcement records)
Which regions and regulatory channels drive supplier visibility?
Supplier availability and public documentation vary by market:
- EU: SmPC manufacturing site disclosures and CEP/DMF references appear in product dossiers
- US: DMF/letters of authorization govern API access more than public packaging labels
- UK/other: national submissions and product listings drive visibility
Procurement teams should align supplier selection to the regulatory channel used for the target market authorization.
Key Takeaways
- Melphalan hydrochloride supply in the market often appears first through finished-dose product supply channels; direct API plant identification requires regulatory dossier cross-checking.
- Supplier names visible in procurement and product ecosystems commonly include Aspen, Viatris, Teva, Accord Healthcare, and legacy footprints such as Pfizer/Hospira depending on jurisdiction.
- To qualify the true API manufacturing source, buyers should map finished product sites to API DMF/CEP references and request GMP, CoA, specs, stability, and regulatory documentation.
FAQs
1) Is the listed finished-product supplier the same as the melphalan hydrochloride API manufacturer?
Not always. Labels and product listings often identify the MAH or finished-dose manufacturer. API manufacturing requires dossier-level confirmation.
2) Where do buyers typically find the manufacturing sites for melphalan-containing products?
In EU/EEA and many other markets, the SmPC and regulator product listings provide manufacturing site disclosures.
3) What documentation best verifies API quality for melphalan hydrochloride?
GMP certificate for the API site, lot CoA, full specifications, impurity profile/limits, and stability summary.
4) What is the main CMC risk when switching melphalan hydrochloride suppliers?
Differences in impurity profiles and process-related residues can affect control strategies and regulatory comparability.
5) How do buyers reduce supply disruption risk?
Source through suppliers with multiple qualified sites or robust continuity planning, and confirm re-test periods, batch frequency, and change-control history.
References
[1] European Medicines Agency (EMA). Product information and EPAR/SmPC framework (general reference for manufacturing site disclosure approach). https://www.ema.europa.eu/
[2] U.S. FDA. DMF and regulatory reference framework for API documentation (general reference). https://www.fda.gov/industry/chemistry-manufacturing-and-controls-dmf
